source
- Recon: Sino, Boehringer ink cancer drug deal worth $7B; CVS to split pharmacy business from insuranceWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 4d ago↗ source
- Big pharma Q3 earnings roll out as FDA launches rare-disease initiative and uniQure's Huntington's gene therapy enters reviewOver the past week, a dozen major pharmaceutical companies reported third‑quarter results, including AstraZeneca, Biogen, GSK, Bristol Myers Squibb, Merck, Sanofi, AbbVie and Regeneron. Pfizer pos…